# Izumi City General Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/izumi-city-general-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 113 |
| Citations | 43,620 |
| City | Osaka |
| Country | JP |
| Description | Izumi City General Hospital is a research organisation in Osaka, JP. OpenAlex records 1,428 works and 43,620 citations for it. 439 researchers list it as their most recent affiliation. |
| Homepage | https://izumi.tokushukai.or.jp/ |
| OpenAlex ID | https://openalex.org/I4210132249 |
| Researchers | 439 |
| ROR ID | https://ror.org/03yj19r32 |
| Type | healthcare |
| Works | 1,428 |

## University papers

Showing 12 of 13.

- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial](https://scholariq.org/papers/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung/)
- [EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors](https://scholariq.org/papers/eml4-alk-mutations-in-lung-cancer-that-confer-resistance-to-alk-inhibitors/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-of-the-mage-a3-cancer-immunotherapeutic-as-adjuvant-therapy-in-patients/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer](https://scholariq.org/papers/a-single-arm-study-of-sublobar-resection-for-ground-glass-opacity-dominant/)
- [Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia](https://scholariq.org/papers/genome-wide-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)
- [Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-clinical-practice-guidelines-for-the-management-of-patients/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Thyroid Cancer Diagnosis and Treatment](https://scholariq.org/topics/thyroid-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.